Compounds > bw-a 78u
Page last updated: 2024-12-07

bw-a 78u

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9-(2-fluorobenzyl)-6-(methylamino)-9H-purine: RN from first source; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127779
CHEMBL ID445098
CHEMBL ID7359
SCHEMBL ID1883213
MeSH IDM0144143

Synonyms (30)

Synonym
bw-a 78u
bw-a78u
9-(2-fluorobenzyl)-6-(methylamino)-9h-purine
bw a78u
9h-purin-6-amine, 9-((2-fluorophenyl)methyl)-n-methyl-
9-((2-fluorophenyl)methyl)-n-methyl-9h-purin-6-amine
brn 4517870
bw-a-78u
CHEMBL445098 ,
CHEMBL7359
bdbm50058210
[9-(2-fluoro-benzyl)-9h-purin-6-yl]-methyl-amine; compound with methanesulfonic acid
9-[(2-fluorophenyl)methyl]-n-methylpurin-6-amine
SCHEMBL1883213
dx8s5q0n0s ,
unii-dx8s5q0n0s
101155-02-6
S6576
DTXSID50143759
AKOS030562250
CS-0018097
HY-100118
bwa-78u
A17098
BCP30171
bw a78u;bw-a 78u;bw-a78u
9h-purin-6-amine, 9-[(2-fluorophenyl)methyl]-n-methyl-
9-(2-fluorobenzyl)-n-methyl-9h-purin-6-amine
MS-23624
EX-A3196
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID184623Compound was evaluated for the anticonvulsant activity in rats.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
9-(2-Fluorobenzyl)-6-(methylamino)-9H-purine hydrochloride. Synthesis and anticonvulsant activity.
AID177407Compound was evaluated for the anticonvulsant activity by testing its ability to protect against maximal electroshock- induced seizures in rats; Intraperitoneal administration (ip)1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
9-(2-Fluorobenzyl)-6-(methylamino)-9H-purine hydrochloride. Synthesis and anticonvulsant activity.
AID25598Dissociation constant was measured1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
8-Amino-3-benzyl-1,2,4-triazolo[4,3-a]pyrazines. Synthesis and anticonvulsant activity.
AID180363The compound was tested for anticonvulsant activity against Maximal Electroshock-Induced Seizures(MES) in Wistar male rat, after peroral administration.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
8-Amino-3-benzyl-1,2,4-triazolo[4,3-a]pyrazines. Synthesis and anticonvulsant activity.
AID19841Lipophilicity was measured1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
8-Amino-3-benzyl-1,2,4-triazolo[4,3-a]pyrazines. Synthesis and anticonvulsant activity.
AID180362The compound was tested for anticonvulsant activity against Maximal Electroshock-Induced Seizures(MES) in intraperitoneal administration.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
8-Amino-3-benzyl-1,2,4-triazolo[4,3-a]pyrazines. Synthesis and anticonvulsant activity.
AID177270Compound was evaluated for the anticonvulsant activity by testing its ability to protect against maximal electroshock- induced seizures in rats after peroral administration (po)1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
9-(2-Fluorobenzyl)-6-(methylamino)-9H-purine hydrochloride. Synthesis and anticonvulsant activity.
AID26123pKa value of the compound1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis and anticonvulsant activity of N-benzylpyrrolo[2,3-d]-, -pyrazolo[3,4-d]-, and -triazolo[4,5-d]pyrimidines: imidazole ring-modified analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine.
AID180365The compound was tested for anticonvulsant activity against maximal electroshock-induced seizures after peroral administration in rats1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis and anticonvulsant activity of N-benzylpyrrolo[2,3-d]-, -pyrazolo[3,4-d]-, and -triazolo[4,5-d]pyrimidines: imidazole ring-modified analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine.
AID180364The compound was tested for anticonvulsant activity against maximal electroshock-induced seizures after intraperitoneal administration in rats1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis and anticonvulsant activity of N-benzylpyrrolo[2,3-d]-, -pyrazolo[3,4-d]-, and -triazolo[4,5-d]pyrimidines: imidazole ring-modified analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine.
AID178281Anticonvulsant activity against maximal electroshock-induced seizures in Wistar rats following i.p. administration.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
1-(Fluorobenzyl)-4-amino-1H-1,2,3-triazolo[4,5-c]pyridines: synthesis and anticonvulsant activity.
AID113150Concentration required to protect 50 % of mice against hind limb extensor component in MES test when administered perorally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
9-(2-Fluorobenzyl)-6-(methylamino)-9H-purine hydrochloride. Synthesis and anticonvulsant activity.
AID178283Anticonvulsant activity against maximal electroshock-induced seizures in rats after intraperitoneal administration.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
9-(2-Fluorobenzyl)-6-(alkylamino)-9H-purines. A new class of anticonvulsant agents.
AID178282Anticonvulsant activity against maximal electroshock-induced seizures in Wistar rats following p.o. administration.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
1-(Fluorobenzyl)-4-amino-1H-1,2,3-triazolo[4,5-c]pyridines: synthesis and anticonvulsant activity.
AID113148Concentration required to protect 50 % of mice against hind limb extensor component in MES test when administered intraperitoneally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
9-(2-Fluorobenzyl)-6-(methylamino)-9H-purine hydrochloride. Synthesis and anticonvulsant activity.
AID177408Compound was evaluated for the anticonvulsant activity by testing its ability to protect against maximal electroshock- induced seizures in rats; Intravenous administration (iv)1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
9-(2-Fluorobenzyl)-6-(methylamino)-9H-purine hydrochloride. Synthesis and anticonvulsant activity.
AID19691Partition coefficient (logP)1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Synthesis and anticonvulsant activity of N-benzylpyrrolo[2,3-d]-, -pyrazolo[3,4-d]-, and -triazolo[4,5-d]pyrimidines: imidazole ring-modified analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine.
AID178284Anticonvulsant activity against maximal electroshock-induced seizures in rats after oral administration1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
9-(2-Fluorobenzyl)-6-(alkylamino)-9H-purines. A new class of anticonvulsant agents.
AID113149Concentration required to protect 50 % of mice against hind limb extensor component in MES test when administered intravenously1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
9-(2-Fluorobenzyl)-6-(methylamino)-9H-purine hydrochloride. Synthesis and anticonvulsant activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's6 (75.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		1.99106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
phenytoin
[no description available]		3.0750imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
9-(2-hydroxy-3-nonyl)adenine
9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase		1.9910
rolipram
[no description available]		1.9710pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
pentylenetetrazole
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.		1.9710organic heterobicyclic compound;
organonitrogen heterocyclic compound
cyclic gmp
Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.		1.99103',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure
[description not available]		02.6630
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.6630